Clearmind Medicine has filed a patent for a new combination therapy for addiction, involving Ibogaine and Palmitoylethanolamide (PEA). The therapy, developed in collaboration with SciSparc, aims to improve the safety and efficacy of Ibogaine-based treatments for opioid, cocaine, and other substance use disorders.
Results for: Addiction Treatment
The global substance abuse treatment market is experiencing rapid growth, driven by rising addiction rates and increasing acceptance of innovative treatment options. The market is projected to reach $22.8 billion by 2031, with a CAGR of 5.4% from 2023 to 2031. This growth is fueled by factors such as greater social acceptance of substance use, increased availability of illicit drugs, stress, and mental health issues. The market is also benefiting from the adoption of digital therapeutic solutions and the development of new and more effective drugs.